A detailed history of Ameriprise Financial Inc transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 45,647 shares of MRSN stock, worth $115,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,647
Previous 45,547 0.22%
Holding current value
$115,030
Previous $91,000 5.49%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.23 - $2.25 $123 - $225
100 Added 0.22%
45,647 $86,000
Q2 2024

Aug 14, 2024

BUY
$2.0 - $4.45 $55,274 - $122,984
27,637 Added 154.31%
45,547 $91,000
Q1 2024

May 15, 2024

SELL
$2.16 - $5.94 $49,883 - $137,178
-23,094 Reduced 56.32%
17,910 $80,000
Q4 2023

Feb 14, 2024

BUY
$1.11 - $2.34 $45,514 - $95,949
41,004 New
41,004 $95,000
Q2 2023

Aug 14, 2023

BUY
$3.08 - $9.55 $1.76 Million - $5.47 Million
572,273 New
572,273 $1.88 Million
Q4 2022

Feb 14, 2023

SELL
$5.65 - $7.86 $1,841 - $2,562
-326 Reduced 1.19%
27,044 $158,000
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $126,723 - $218,960
27,370 New
27,370 $185,000
Q1 2021

May 17, 2021

SELL
$15.31 - $26.52 $129,139 - $223,696
-8,435 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$16.84 - $27.59 $142,045 - $232,721
8,435 New
8,435 $225,000
Q4 2019

Feb 14, 2020

SELL
$1.45 - $6.73 $28,253 - $131,134
-19,485 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$1.54 - $4.2 $31,386 - $85,600
-20,381 Reduced 51.12%
19,485 $31,000
Q2 2019

Aug 14, 2019

BUY
$3.84 - $6.4 $153,085 - $255,142
39,866 New
39,866 $161,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $245M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.